Diabetes and insulin

Diabetes and insulin

1.  Presented by
 RaselMahbub
 Dept of pharmacy
 JagannathUniversity


2. DM is characterized by elevated blood
sugar levels due to absolute or relative
lack of insulin.
Type 1 diabetes--cell failure at outset
•Insulin dependent
Type 2 diabetes-Gradual -cell
deterioration
•Early stages: Diet and Oral agents
•Late-stage: Insulin therapy

3. Glycosylated hemoglobin Hb-A1c :
It is used to monitor the plasma glucose
concentration over prolonged periods of
time (4-6 weeks).
Insulin secretion is promoted by ↑blood
glucose levels, amino acids, GI hormones
and by β-2 agonist.

4. Proinsulin is converted to insulin and C
peptide.
Insulin is referred as the storage hormone
as it promotes anabolism and inhibits
catabolism of carbohydrates, fatty acids
and protein.
In the absence of insulin, most tissues
cannot use glucose and fats/proteins are
broken down to provide energy.

5. Mechanism of action :
Insulin binds to insulin receptors on the
plasma membrane and activates tyrosine
kinase –primarily in adipose tissue,
liver and skeletal muscle.
The Nerves, RBC’s, Kidney, and Lens of
the eye do notrequire insulin for
glucose transport.

6. Liver :
Insulin increase the storage of glucose as
glycogen in the liver.
It inserts the GLUT-2glucose transport
molecule in the cell membrane.
It inhibits gluconeogenesis –thus
significantly ↓ glucose output by the liver.
It decrease the protein catabolism.

8. Muscle :
Insulin stimulates the glycogen
synthesis and protein synthesis.
Glucose transport into the cells is
facilitated by GLUT-4into the cell
membrane.
It inhibits the protein catabolism.

9. Adipose tissue :
Insulin facilitates the storage of
triglyceride by activating plasma
lipoprotein lipase and inhibiting
intracellular lipolysis.
It increase the glucose uptake by
GLUT-4insertion into the cell
membrane.

11. Insulin is a 51 AA peptide
Not active orally.
Insulin is inactivated by insulinase found
mainly in liver and kidney.
Dose reduced in renal insufficiency
Sources of Insulin :
•Beef pancreas / Pork pancreas
•Human insulin: recombinant DNA origin

12. Human Insulin :
Do not contain measurable amounts of
proinsulin or contaminants.
Diminished antibody
Less allergic reactions
Less lipodystrophy
Preferred in gestational diabetes

13. Insulin preparations :
Rapid acting insulin : Lispro,
Aspart and Glulisine
Short acting insulin:
Regular (crystalline)
Intermediate acting insulin: NPH
(isophane)and Lente (insulin zinc)
Long acting insulin:
Ultralente,Detimir and Glargine

14. Insulin Duration Route Features
Lispro 3 –5 hrs I.V or S.C
Onset within 15
minutes
Regular
(crystalline)
7 –10 hrsI.V or S.Ccommon
NPH
(Neutral protamine
hagedorn)
16 –20 hrs S.C
NPH can mix
with regular
Ultralente24 –30 hrsS.C Basal level

15. Insulin

16. Adverse effects of Insulin :
Hypoglycemia
Allergic reactions
Lipodystrophy
Others includes
•Seizures
•Coma

17. Mechanisms to reduce blood sugar :
Stimulation of pancreatic insulin release–
Sulfonylureas, Meglitinide
Reduce the bio-synthesis of glucose in
liver –Biguanides (Metformin)
Increase the sensitivity of target cells to
insulin --Thiazolidinediones
Retard the absorption of sugars from the
GI tract–Acarbose, Miglitol

19. Sulfonylureas :
First generation :Acetohexamide,
Chlorpropamide, Tolbutamide,
Tolazamide
Second generation :Glipizide, Glyburide
–more potent, more efficacious and fewer
adverse effects.
Third generation :Glimiperide

20. Sulfonylureas

21. Sulfonylureas
Dose
(mg)
Duration
(h)
First Generation
Tolbutamide (Orinase) 1000-1500 6-8
Chlorpropamide (Diabinese) 250-375 24-60
Tolazamide (Tolinase) 250-375 12-24
Second generation
Glipizide (Glucotrol) 10 10-24
Glyburide (Micronase)
(Glibenclamide)
Third generation
5 16-24
Glimepiride (Amaryl) 1-2 24

22. Sulfonylureas : Adverse effects :
Hypoglycemia
Cholestatic jaundice
Weight gain
Cross placenta –fetal hypoglycemia.
Chlorpropamide : It can cause water
retention by ↑ release of ADH (SIADH)
Disulfiram-like reaction with alcohol.

23. Repaglinide, Nateglinide :
More rapidly acting insulin enhancers
and shorter duration than sulfonylurea.
Hypoglycemia is the common adverse
effect.
Less weight gain

24. Repaglinide, Nateglinide
The drug has minimal renal excretion thus
useful in patients with DM and impaired
renal function.
It is designed to be taken with each meal
to stimulate insulin release with meal.
If a meal is skipped, so is the repaglinide.

25. Biguanides (Metformin):
Inhibits gluconeogenesis.
Does not promote insulin secretion.
It increase the sensitivity of liver and
muscle to insulin.
It causes modest weight loss.

26. Metformin (Glucophage):
It does not cause hypoglycemia.
It produces a significant ↓TG and LDL,
and ↑HDL.
There is a serious concern about lactic
acidosis especially in patients with kidney
disease.

27. Thiazolidinediones
Enhance glucose and lipid metabolism
through action on Peroxisome Proliferator
Activated Receptor (PPAR–γ)
Enhance sensitivity to insulin in muscle
and fat by increasing the GLUT 4 glucose
transporters.
E.g. ; Pioglitazone Actos,Rosiglitazone
Avandia

28. Thiazolidinediones :
Beneficial effects on serum lipid; ↓TG and
↑HDL.
Troglitazone is associated with hepatitis.
Edema.

29. Alpha-Glucosidase Inhibitors:
It inhibits -glucosidase which converts
dietary starch and complex
carbohydrates into simple sugars
It reduces absorption of glucose after
meals.
The main side effects includes flatulence
and diarrhea.
Acarbose (Glucobay), Miglitol (Glyset)

31. Glucagon like Peptide : GLP-1 analog :
Xenatide : (Byetta) :
GLP is an incretin released from the small
intestine which increase the glucose
dependent insulin secretion.
Xenatide suppress glucagon release and
reduce appetite
It is administered by SC injection.

32. Glucagon like Peptide : GLP-1 analog :Xenatide : (Byetta) :

33. Dipeptidyl peptidase 4 (DPP-4) inhibitors: SITAGLIPTIN (januvia)
Xenatide
(Byetta) inj
Sitagliptin
(januvia)

34. Sitagliptin(Januvia)is an oral anti-
diabetic drug.
It inhibit the dipeptidyl peptidase 4 (DPP-
4), an enzyme which inactivates the
incretins GLP-1 and GIP, that are released
in response to a meal.
It potentiates the secretion of insulin and
suppress the release of glucagon by the
pancreas.

35. Glucagon :
It has positive inotropic action and
chronotropic action on the heart.
It acts by stimulation of glucagon
receptors and not through beta 1 receptors.
This is the basis for using glucagon in beta
blocker overdose.